PL206190B1 - Kompozycja farmaceutyczna zawierająca prawastatynę i aspirynę - Google Patents

Kompozycja farmaceutyczna zawierająca prawastatynę i aspirynę

Info

Publication number
PL206190B1
PL206190B1 PL377265A PL37726503A PL206190B1 PL 206190 B1 PL206190 B1 PL 206190B1 PL 377265 A PL377265 A PL 377265A PL 37726503 A PL37726503 A PL 37726503A PL 206190 B1 PL206190 B1 PL 206190B1
Authority
PL
Poland
Prior art keywords
layer
aspirin
tablet
pravastatin
sodium
Prior art date
Application number
PL377265A
Other languages
English (en)
Polish (pl)
Other versions
PL377265A1 (pl
Inventor
Loutfy Benkerrour
Olivier Galley
Francoise Quinet
Admassu Abebe
Peter Timmins
Original Assignee
Bristol Myers Squibb Companybristol Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32505946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL206190(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Companybristol Myers Squibb Company filed Critical Bristol Myers Squibb Companybristol Myers Squibb Company
Publication of PL377265A1 publication Critical patent/PL377265A1/pl
Publication of PL206190B1 publication Critical patent/PL206190B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL377265A 2002-12-11 2003-12-03 Kompozycja farmaceutyczna zawierająca prawastatynę i aspirynę PL206190B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/316,424 US20040115265A1 (en) 2002-12-11 2002-12-11 Multilayered tablet containing pravastatin and aspirin and method

Publications (2)

Publication Number Publication Date
PL377265A1 PL377265A1 (pl) 2006-01-23
PL206190B1 true PL206190B1 (pl) 2010-07-30

Family

ID=32505946

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377265A PL206190B1 (pl) 2002-12-11 2003-12-03 Kompozycja farmaceutyczna zawierająca prawastatynę i aspirynę

Country Status (17)

Country Link
US (1) US20040115265A1 (enExample)
EP (1) EP1581194B1 (enExample)
JP (1) JP2006511520A (enExample)
AT (1) ATE401061T1 (enExample)
AU (1) AU2003297689A1 (enExample)
CY (1) CY1108414T1 (enExample)
DE (1) DE60322264D1 (enExample)
DK (1) DK1581194T3 (enExample)
ES (1) ES2308040T3 (enExample)
IS (1) IS2877B (enExample)
MY (1) MY140947A (enExample)
NO (1) NO338696B1 (enExample)
PL (1) PL206190B1 (enExample)
PT (1) PT1581194E (enExample)
SI (1) SI1581194T1 (enExample)
TW (1) TWI361700B (enExample)
WO (1) WO2004052289A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
US20060251722A1 (en) * 2005-05-03 2006-11-09 Novavax, Inc. Multi-component vitamin and mineral supplement for the optimal absorption of components
WO2007027566A2 (en) * 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
JP2009514966A (ja) * 2005-11-08 2009-04-09 ジェンザイム・コーポレーション 高リン血症のためのマグネシウム含有重合体
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007072060A2 (en) * 2005-12-23 2007-06-28 Cipla Limited Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
DK2089005T3 (da) * 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
WO2008112706A1 (en) 2007-03-13 2008-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
KR101330096B1 (ko) * 2007-10-12 2013-11-15 페링 인터내셔널 센터 에스 에이 구연산, 산화 마그네슘, 중탄산칼륨 및 피코황산나트륨을 포함하는 의약품의 제조 방법, 이러한 방법에 의해 제조된 과립을 포함하는 약제학적 조성물 및 중간체
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
TR201005325A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 HMG-CoA 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
JP5905031B2 (ja) * 2011-01-28 2016-04-20 インタッチ テクノロジーズ インコーポレイテッド モバイルテレプレゼンスロボットとのインタフェーシング
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness
JP7109748B2 (ja) * 2018-12-11 2022-08-01 日本ジェネリック株式会社 アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
EP1063973B1 (en) * 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
EP1581194B1 (en) 2008-07-16
TW200505432A (en) 2005-02-16
CY1108414T1 (el) 2014-02-12
WO2004052289A3 (en) 2005-03-24
IS7889A (is) 2005-06-10
NO20052734D0 (no) 2005-06-07
DE60322264D1 (de) 2008-08-28
US20040115265A1 (en) 2004-06-17
PL377265A1 (pl) 2006-01-23
ES2308040T3 (es) 2008-12-01
NO338696B1 (no) 2016-10-03
TWI361700B (en) 2012-04-11
AU2003297689A8 (en) 2004-06-30
AU2003297689A1 (en) 2004-06-30
EP1581194A4 (en) 2006-03-15
ATE401061T1 (de) 2008-08-15
DK1581194T3 (da) 2008-10-20
EP1581194A2 (en) 2005-10-05
WO2004052289A2 (en) 2004-06-24
JP2006511520A (ja) 2006-04-06
SI1581194T1 (sl) 2008-12-31
NO20052734L (no) 2005-07-07
MY140947A (en) 2010-02-12
PT1581194E (pt) 2008-09-24
IS2877B (is) 2014-04-15

Similar Documents

Publication Publication Date Title
EP1581194B1 (en) Multilayered tablet containing pravastatin and aspirin and method
AU760520B2 (en) Pharmaceutical composition containing a statin and aspirin
EP0493408B1 (en) Oral anticoagulant/platelet inhibitor low dose formulation
US20110008426A1 (en) Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
US9642808B2 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
WO2008075320A2 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
KR102283582B1 (ko) 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
WO2009010810A2 (en) Cardiovascular combinations comprising ace and hmg-co-a inhibitors
KR102081095B1 (ko) 페노피브릭산 또는 이의 약학적으로 허용 가능한 염을 포함하는 장용성 코팅 정제
KR102882732B1 (ko) 고혈압 치료용 복합 약제학적 조성물
US11737988B2 (en) Anti-hypertensive and cholesterol-lowering fixed-dose combination and method of manufacture
CA2624838C (en) Retard formulation for pralnacasan
KR101072600B1 (ko) 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법
KR20200015639A (ko) 페노피브릭산 또는 이의 약학적으로 허용 가능한 염을 포함하는 장용성 코팅 정제
MXPA00008429A (en) Pharmaceutical composition containing a statin and aspirin
HU211938A9 (hu) Koagulációt és vérlemezke-működést gátló hatóanyagokat kis dózisban tartalmazó, orális adagolású gyógyszerkészítmények Az átmeneti oltalom a 2-24. igénypontokra vonatkozik.

Legal Events

Date Code Title Description
RECP Rectifications of patent specification